Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 5/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.39 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148605 | 0.84 | SIGMAR1 (0.43) | GAA | |
| SCHEMBL5150635 | 0.82 | HDAC6 (0.38) | GAA | |
| SCHEMBL6426568 | 0.81 | MEN1 (0.38) | LPAR1TRPV4 | |
| SCHEMBL5148558 | 0.80 | MEN1 (0.33) | — | |
| SCHEMBL5147593 | 0.79 | CYP4F2 (0.48) | GAA | |
| SCHEMBL5148648 | 0.78 | POLB (0.34) | GAALPAR1 | |
| SCHEMBL6425375 | 0.78 | LPAR1 (0.36) | GAANPC1RAB9ALPAR1 | |
| SCHEMBL5148585 | 0.76 | MEN1 (0.38) | — | |
| SCHEMBL5147620 | 0.76 | KIF11 (0.36) | — | |
| SCHEMBL5492718 | 0.72 | BCHE (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179801-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1392704-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20040248875-A1 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248875-A1 | Cephem compounds | CEP170, C1S, SLC7A1 | MTNR1B 2879/4885MTNR1A 2694/4885LTA4H 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.